Cellectis S.A.

ALCLS

FR0010425595

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 12:48:24 13/01/2026 GMT			5-day change	1st Jan Change
3.680 ^EUR	+1.52%		-6.12%	-12.28%

12-30	European Equities Traded in the US as American Depositary Receipts Rise Tuesday	MT
12-29	European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	MT

European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading

Published on 11/26/2025 at 04:07 pm GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Cellectis S.A.

12-30	European Equities Traded in the US as American Depositary Receipts Rise Tuesday	MT
12-29	European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	MT
12-26	European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week	MT
12-23	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
12-22	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
12-19	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Slightly Higher for Week	MT
12-18	European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading	MT
12-16	European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	MT
12-16	Cellectis shares fall after arbitration in dispute with Servier
12-15	Cellectis announces arbitral decision in dispute with Servier	RE
12-15	Cellectis S.A. - Analyst/Investor Day
12-12	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week	MT
12-11	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
12-10	European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	MT
12-09	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
12-08	Encouraging Phase 1 Data for Cellectis in Non-Hodgkin Lymphoma
12-08	Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL	CI
12-01	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
11-26	European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading	MT
11-24	European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading	MT
11-21	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down 3% for Week	MT
11-20	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
11-19	European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	MT
11-19	Cellectis Publishes Nature Communications Article on A Non-Viral Gene Editing	CI
11-19	Cellectis stands out after advances in gene insertion

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR T cells for the treatment of cancer patients, and a platform for for the development of gene therapies in other therapeutic indications. Thanks to its fully in-house production capabilities, Cellectis S.A. is one of the few genome-editing companies to control the cell and gene therapy value chain from end to end.

Employees

219

Sector

Biotechnology & Medical Research

Calendar

01-28 - Allinvest Securities Biomed Forum

More about the company